Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

Passaro, A.; Wang, J.; Shah, S.; Bauml, J. M.; Campelo, R. G.; Cho, B. C.

doi:10.1016/j.annonc.2023.11.012

YUHSpace

BROWSE

0 157

Cited 0 times in

Cited 3 times in

Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

Authors: Passaro, A. ; Wang, J. ; Shah, S. ; Bauml, J. M. ; Campelo, R. G. ; Cho, B. C.

Citation: ANNALS OF ONCOLOGY, Vol.35(3) : 328-329, 2024-03

Journal Title: ANNALS OF ONCOLOGY

ISSN: 0923-7534

Issue Date: 2024-03

Abstract: [No abstract available]

DOI: 10.1016/j.annonc.2023.11.012

Appears in Collections:: 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

Yonsei Authors: Cho, Byoung Chul(조병철) https://orcid.org/0000-0002-5562-270X

URI: https://ir.ymlib.yonsei.ac.kr/handle/22282913/200572

사서에게 알리기

Show full item record Find it @ YMLIB

License

YUHSpace: Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

YUHSpace

BROWSE

Browse

Links